BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 15613106)

  • 1. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia.
    Steensma DP; Gibbons RJ; Mesa RA; Tefferi A; Higgs DR
    Eur J Haematol; 2005 Jan; 74(1):47-53. PubMed ID: 15613106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome.
    Nakao M; Horiike S; Fukushima-Nakase Y; Nishimura M; Fujita Y; Taniwaki M; Okuda T
    Br J Haematol; 2004 Jun; 125(6):709-19. PubMed ID: 15180860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
    Harada Y; Harada H
    J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome.
    Chen CY; Lin LI; Tang JL; Ko BS; Tsay W; Chou WC; Yao M; Wu SJ; Tseng MH; Tien HF
    Br J Haematol; 2007 Nov; 139(3):405-14. PubMed ID: 17910630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Familial platelet disorder with propensity to acute myelogenous leukemia: genetic heterogeneity and progression to leukemia via acquisition of clonal chromosome anomalies.
    Minelli A; Maserati E; Rossi G; Bernardo ME; De Stefano P; Cecchini MP; Valli R; Albano V; Pierani P; Leszl A; Sainati L; Lo Curto F; Danesino C; Locatelli F; Pasquali F
    Genes Chromosomes Cancer; 2004 Jul; 40(3):165-71. PubMed ID: 15138996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.
    Osato M
    Oncogene; 2004 May; 23(24):4284-96. PubMed ID: 15156185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
    Harada Y; Harada H
    J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia.
    Harada H; Harada Y; Niimi H; Kyo T; Kimura A; Inaba T
    Blood; 2004 Mar; 103(6):2316-24. PubMed ID: 14615365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AML1/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies.
    Taketani T; Taki T; Takita J; Tsuchida M; Hanada R; Hongo T; Kaneko T; Manabe A; Ida K; Hayashi Y
    Genes Chromosomes Cancer; 2003 Sep; 38(1):1-7. PubMed ID: 12874780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
    Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
    Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AML1/RUNX1 gene point mutations in childhood myeloid malignancies.
    Migas A; Savva N; Mishkova O; Aleinikova OV
    Pediatr Blood Cancer; 2011 Oct; 57(4):583-7. PubMed ID: 21294243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Distinct genetic pathway in the molecular pathogenesis of MDS/AML with AML1/RUNX1 point mutations].
    Harada H
    Rinsho Ketsueki; 2007 Jul; 48(7):541-6. PubMed ID: 17695302
    [No Abstract]   [Full Text] [Related]  

  • 13. Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes.
    Wulfert M; Küpper AC; Tapprich C; Bottomley SS; Bowen D; Germing U; Haas R; Gattermann N
    Exp Hematol; 2008 May; 36(5):577-86. PubMed ID: 18439489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of RUNX1/AML1 as a classical tumor suppressor gene.
    Silva FP; Morolli B; Storlazzi CT; Anelli L; Wessels H; Bezrookove V; Kluin-Nelemans HC; Giphart-Gassler M
    Oncogene; 2003 Jan; 22(4):538-47. PubMed ID: 12555067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analyses of the mutations of AML 1 gene in myelodysplastic syndromes].
    Yoichi I
    Rinsho Ketsueki; 2002 Mar; 43(3):139-45. PubMed ID: 11979742
    [No Abstract]   [Full Text] [Related]  

  • 16. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia.
    Harada H; Harada Y; Tanaka H; Kimura A; Inaba T
    Blood; 2003 Jan; 101(2):673-80. PubMed ID: 12393679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21.
    Preudhomme C; Warot-Loze D; Roumier C; Grardel-Duflos N; Garand R; Lai JL; Dastugue N; Macintyre E; Denis C; Bauters F; Kerckaert JP; Cosson A; Fenaux P
    Blood; 2000 Oct; 96(8):2862-9. PubMed ID: 11023523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice.
    Yanagida M; Osato M; Yamashita N; Liqun H; Jacob B; Wu F; Cao X; Nakamura T; Yokomizo T; Takahashi S; Yamamoto M; Shigesada K; Ito Y
    Oncogene; 2005 Jun; 24(28):4477-85. PubMed ID: 15856017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Core binding factor genes and human leukemia.
    Hart SM; Foroni L
    Haematologica; 2002 Dec; 87(12):1307-23. PubMed ID: 12495904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Familial myelodysplasia and acute myeloid leukaemia--a review.
    Owen C; Barnett M; Fitzgibbon J
    Br J Haematol; 2008 Jan; 140(2):123-32. PubMed ID: 18173751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.